BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints
Go back to BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints(NASDAQ: BGNE) | Delayed: 168.50 -1.5 (0.88%) | |||||
---|---|---|---|---|---|---|
Previous Close | $170.00 | 52 Week High | $36.76 | |||
Open | $168.33 | 52 Week Low | $22.51 | |||
Day High | $170.78 | P/E | N/A | |||
Day Low | $168.33 | EPS | $0.00 | |||
Volume | 154,982 |